Cemiplimab

EU Regulators Back Libtayo as Adjuvant Therapy for High-Risk Cutaneous Squamous Cell Carcinoma

The move reflects phase 3 C-POST evidence showing a substantial disease-free survival benefit in resected high-risk CSCC.